

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/44		A1	(11) International Publication Number: WO 98/06395
			(43) International Publication Date: 19 February 1998 (19.02.98)
(21) International Application Number: PCT/US97/13968		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UC, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 12 August 1997 (12.08.97)		Published <i>With international search report.</i>	
(30) Priority Data: 08/695,393 12 August 1996 (12.08.96) US			
(71)/(72) Applicant and Inventor: MILLER, Bruce [US/US]; 4450 Gulf Boulevard #316, St. Pete Beach, FL 33708 (US).			
(74) Agent: NISSENBAUM, Israel; Graham & James LLP, 885 Third Avenue, New York, NY 10022 (US).			
(54) Title: TOPICAL COMPOSITION FOR BURN HEALING			
(57) Abstract			
<p>A method of treating skin includes applying a topical composition to an affected area of skin, such as a burn, irritation, blister, rash or other similar skin condition. The topical composition has as the active ingredients an anesthetic and a surfactant. The anesthetic is preferably tetracaine in a concentration of from about 1 % to 2 % by weight and the surfactant is preferably sodium lauryl sulfate in a concentration of from about 0.5 % to about 5.0 % by weight.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Montenegro	UA	Ukraine
BR	Brazil	IL	Israel	MW	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	NO	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NK	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

TOPICAL COMPOSITION FOR BURN HEALING

BACKGROUND OF THE INVENTION

5 The present invention relates to a topical composition having medicinal properties, in particular, it relates to a topical composition for use in treating burns, scalds, blisters, rash, scabs or other skin conditions experienced by human skin.

10 Burns cause inflammation of the skin, pain and swelling and may result in scabbing and scarring. Skin burns are a complex inflammatory process causing dyskeratotic cells, spongiosis, vacuolation of keratinocytes and edema from capillary leakage, 12 to 24 hours after exposure to light or high temperature. In addition to redness and pain, blisters may develop and scabs and scars may result.

15 Known treatments for burns are limited in efficacy. The topical use of anti-inflammatory agents to alleviate inflammation resulting from burns is known. Compositions containing steroidial anti-inflammatories, non-steroidal anti-inflammatories, as well as "natural" anti-inflammatories, such as extract of the plant aloe vera, have been used.

20 In the past there have been many salves for the topical treatment of human skin. Although most known salves or ointments have medicinal or soothing characteristics, they do not aid in preventing blistering or scabs and reducing or eliminating scarring of the skin tissue or have an immediate effect on the reduction of pain.

SUMMARY OF THE INVENTION

25 The preferred embodiments of the present invention provide topical compositions and methods of use thereof for the alleviation of the symptoms associated with burns of human skin. The preferred embodiments of the present invention also provide a method of applying topical compositions for alleviation of the symptoms of burns with no side effects and

relief from inflammation and pain normally associated with burns while preventing or reducing scabbing and scarring of the skin.

The preferred embodiments of the present invention
5 provide a topical composition for reducing the symptoms of burns and shortening time required for healing. The composition preferably comprises a therapeutically effective amount of a combination of anesthetic and a surfactant. Varying amounts of anesthetic and surfactant are preferably
10 used to achieve efficacious results, e.g., for anesthetic concentrations of from about 0.05% to 25% by weight, preferably 0.25% to 10% by weight, and most preferably 1% to 5% by weight, and for surfactant, concentrations of from about 0.05% to 50% by weight, 1% to 10% by weight, and 0.5% to 5% by
15 weight.

In preferred embodiments, the anesthetic is preferably selected from the group consisting of esters, amides, ethers, and combinations thereof and, in particular, topical anesthetics and other anesthetics which may be formulated in accordance with the preferred embodiments of the present invention and applied topically, including procaine,
20 chloroprocaine, tetracaine, propoxycaine, benzocaine, cocaine, proparacaine, bupivacaine, dibucaine, etidocaine, lidocaine, mepivacaine, prilocaine, dyclonine, promazine and combinations thereof.
25

The surfactant is preferably selected from the group consisting of anionic, nonionic, and cationic surfactants and combinations thereof. Suitable ionic surfactants include anionic surfactants such as monovalent salts, e.g., sodium and potassium salts of alkyl, aryl and alkyl-aryl sulfates and sulfonates, particularly those with from about 8 to 22 carbon atoms, and cationic surfactants, such as quaternary ammonium salts. Suitable non-ionic surfactants include polyethylene oxide adducts of fatty alcohols, e.g., alkylated
30 polyoxyethylenes, alkylated polyoxyethylene-polyoxypropylene
35 copolymers, and the surfactant nonoxynol.

The surfactant and the anesthetic are preferably

formulated together in a pharmaceutically acceptable topical carrier, which may comprise one of a number of known acceptable forms. Suitable topical carriers include known aqueous carriers and oleaginous carriers.

5 The composition may also contain one or more additional agents, including antimicrobial agents, anti-viral agents, anti-fungal agents, buffering agents, antioxidants, preservatives, coloring agents, fragrances, lubricants, moisturizers, sunscreens, drying agents and the like and, more 10 specifically, may include ingredients such as stearic acid, lauramide DEA, borax, eucalyptus oil, beeswax, preservative and methylparaben.

15 The preferred embodiments of the present invention also provide a method for reducing the symptoms of burns including swelling, redness, pain, and scarring while also decreasing time required for healing by topically administering a composition according to a preferred embodiment of the present invention to a burn area, preferably at least about once every twelve hours and, more preferably, about every four hours 20 depending upon the amount of pain. The composition is preferably applied to the burn area daily for maximum benefit. Relief is almost immediate, and is characterized by decreased pain, swelling, and more rapid healing as compared with untreated burns. In addition, the topical administration of 25 the composition reduces or prevents scabbing and scarring of the skin affected by the burn.

30 These and other elements, features and advantages of the preferred embodiments of the present invention will be apparent from the following detailed description of the preferred embodiments of the present invention.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

35 The preferred embodiments of the present invention provide a method for applying a topical composition to treat a skin burn, the composition having two essential components, a topical or local anesthetic and a surfactant. An anesthetic

and a surfactant are preferably added to a conventional carrier, such as, a cream, ointment, solution or gel containing appropriate stabilizers, buffers and preservatives for topical application to the burn area.

5 The topical anesthetics of the preferred embodiment of the present invention are esters, ethers or amides and include the following anesthetics which may be included in the compositions according to the preferred embodiments of the present invention. Esters include Tetracaine, Benzocaine, Proparacaine, Procaine, Cocaine (not a legal drug in the United States) and Propoxycaine. Amides include Dibucaine and Lidocaine. Ethers include Dyclonine and Promazine.

10 There are other anesthetics used for injection, e.g., spinal anesthesia, which are not usually listed as topicals but are expected to work well on burns where intact skin does not present a barrier. Some examples of these anesthetics are: Chloroprocaine, Bupivacaine, Etidocaine, Mepivacaine and Prilocaine.

15 In a preferred embodiment, the anesthetic is tetracaine (either as the hydrochloride or other salt or as the free base). Tetracaine is a preferred anesthetic because the anesthetic penetrates skin most effectively, and it is on the FDA monograph list which allows marketing as an over-the-counter (OTC) product for fever blisters and cold sores at concentrations up to 2% by weight.

20 In a preferred embodiment, the anesthetic is combined with a carrier in a concentration range of between approximately 1% and 2% by weight; however, the anesthetic may be present in varying concentrations, for example, between approximately 0.05% and 25% by weight, between approximately 0.25% and 10% by weight, between approximately 0.5% and 10% by weight, and between approximately 1% and 5% by weight. The exact dose of anesthetic to be employed in a given formulation will depend on a number of factors such as the particular 25 anesthetic to be employed. For example, in compositions containing benzocaine as the anesthetic, an exemplary preferred dose range is between approximately 1% and 20% by

weight, in compositions containing lidocaine, an exemplary preferred dose range is between approximately 1% and 20% by weight and in compositions containing tetracaine an exemplary preferred dose is approximately 0.5%.

5 In addition to the local anesthetic, the compositions used in the method of the preferred embodiment of the invention also contain a therapeutically effective amount of a surfactant. Surfactants have been discovered to have a very low degree of toxicity and work to speed the healing process relating to burn areas. The surfactant facilitates 10 penetration of the anesthetic, enhancing the effectiveness of the individual compounds to facilitate healing.

In a preferred embodiment, the surfactant in the formulation is sodium lauryl (or dodecyl) sulfate, also 15 referred to as "SLS", a common surfactant found in toothpaste and other cosmetic preparations, known to "unfold" the tertiary structure of proteins. Sodium lauryl sulfate is an anionic surfactant with a negatively charged sulfate group. Sodium lauryl sulfate is also capable of penetrating intact 20 skin very effectively. Other monovalent sulfur-containing surfactants, e.g., the sodium or potassium alkyl, alkyl-aryl, and aryl sulfates or sulfonates can be used in accordance with a preferred embodiment of the invention.

25 In addition, cationic surfactants may be used, alone or in combination with SLS. An example is trimethyldodecylammonium chloride, a positively charged quaternary ammonium complex which has antimicrobial characteristics. Other quaternary salts, with and without long chain moieties to provide surface activity, may also be 30 useful.

Nonionic surfactants, the most common being nonoxynol, 35 may also be useful. Common nonionic surfactants include nonoxynol, polyoxyethylenes, polyoxyethylene-polyoxypropylene copolymers and alkyl sorbitols.

In a preferred embodiment, the surfactant is preferably combined with a carrier in a concentration range of between approximately 0.5% to 2%, by weight. However, the surfactant

may be present in a concentration of between approximately 0.1% to 10% by weight. The selected surfactants may also be combined in varying concentration ranges, for example, between approximately 0.1% to 20% by weight, between approximately 5

0.05% to 50% by weight, between approximately 1.0% and 10% by weight and between approximately 0.5% and 5.0% by weight.

The composition can also contain antimicrobials, including antibiotics, antifungals, and other anti-viral compounds which may complement or supplement the activity of 10 the basic composition. Suitable antibiotics include tetracycline, polymyxin B or other common antibiotics used in topical compositions, especially over-the-counter formulations. Examples of useful antifungals include tolnaftate and micatin. Examples of anti-virals include 15 interferon, either natural or recombinant, as well as nucleoside analogs, e.g., Acyclovir. Counter-irritants such as camphor and menthol, drying agents such as benzyl alcohol, resorcinol and phenol, and astringents such as zinc sulfate and tannic acid can also be added to the composition as can 20 other types of agents such as sunscreens, emollients, preservatives, fragrances, antioxidants, color additives, lubricants, moisturizers or drying agents. For example, a sunscreen, e.g., PABA, can be added to the formula since it is known that burns can be caused by ultraviolet radiation.

25 The composition used in the method according to the preferred embodiments can be prepared in almost any relatively inert topical carrier. Generally, the formulation could take several forms, e.g., cream, gel, spray, ointment, "Chapstick" and solution forms. Each of these formulations may contain 30 the two active ingredients as well as microorganism growth inhibitors (preservatives). Many such carriers are routinely used and can be obtained by reference to pharmaceutical texts. Examples include polyethylene glycols (PEG), polypropylene copolymers (Pluronics), and some water soluble gels.

35 The preferred carrier is an emulsified cream, but other common carriers such as certain petrolatum or mineral oil-based ointments in which the surfactant and anesthetic are

dispersible can be substituted. For example, one suitable cream formulation used in animal studies and clinical experiments is described below:

	COMPONENT	PERCENT (approximate)
5	Deionized water	69
	Stearic Acid	22
	Sodium lauryl sulfate	1
	Beeswax	1
	Tetracaine	2
	Borax	0.4
10	Lauramide DEA	3.6
	Methylparaben	0.3
	Eucalyptus Oil	0.03

At this time, the preferred composition determined through actual testing to be most effective in enhancing healing of burns is: (all percent's are by weight):

15 methylparaben, 0.25% (0.25% to 0.5%)
 borax, 0.5% (0.3% to 0.6%)
 lauramide DEA, 4% (3.0% to 4.0%)
 20 stearic acid, 20% (15% to 25%)
 beeswax, 0.8% (0.5% to 1.5%)
 tetracaine, 1.8% (1% to 2%)
 sodium lauryl sulfate, 0.8% (0.1% to 3%)
 eucalyptus oil 0.025% (0.01% to 0.05%)
 25 PCMx 0.4% (0.3% to 0.5%)
 water to a total of 100%

30 Gels, i.e., thickened aqueous or alcoholic solutions, containing the active ingredients and stabilizers may be clear and/or colored with suitable dyes. Suitable thickeners may include carboxymethylcellulose, polyvinyl-pyrrolidone or polyacrylic acid salts.

Hydrophilic or hydrophobic ointments may be employed as carriers. However, hydrophobic ointments, such as Vaseline, which are based upon hydrocarbon and wax derivatives may not be as efficacious as the hydrophilic ointments because they may impede penetration into the skin. Hydrophilic ointments such as those based upon propylene glycol, polyalkylene glycols, and the Pluronics are therefore preferred for ointment formulations. Propylene glycol, as a base, is preferable to polyethylene glycol.

"Chapstick" formulations may be employed in situations, e.g., for treatment of burns, where ease of application is a primary objective.

Solutions, i.e., dilute aqueous preparations containing active ingredients and preservatives but without substantial concentrations of thickeners, can be sprayed upon the affected surface with an aerosol pump. This type of delivery may be of value for treating larger areas of painfully sensitive skin.

In most cases, it is preferred that the pH of the carrier containing the active ingredients is adjusted to a pH of about 6 to 7, using, as buffering agents, ingredients such as borax although other acceptable buffering agents could be used.

Additional additives may include antioxidants, fragrance, color, water, preservatives (either antioxidants or antimicrobials), lubricants, moisturizers, or drying agents.

According to a preferred embodiment of the present invention, the composition is preferably applied to the burn area one to six times daily, most preferably beginning immediately after the burn occurs. A liberal amount of the composition is preferably applied to cover the burn area, however, just a thin coating is required to reduce pain, redness and swelling and prevent or reduce blistering, scabbing and scarring.

Examples 1-6 are accounts of persons who have used a composition of a preferred embodiment of the present invention to treat burns.

EXAMPLE 1

A patient received a burn caused by heat emitting from an engine at a temperature of 350 degrees fahrenheit. The burn caused pain and a reddened area on the arm. The patient
5 immediately applied a thin layer of a composition according to a preferred embodiment of the present invention (SLS and Tetracaine) to the reddened area. Within 60 seconds, the pain was eliminated. Within a few hours the redness was eliminated. The patient did not experience any pain except
10 for the initial burn, and no scarring or blistering resulted.

EXAMPLE 2

The same patient as in Example 1 later burned himself as the result of touching a heated gel pack in a microwave oven. The finger area which had touched the gel turned white in
15 color. The patient had developed a second degree burn. A thin layer of the inventive composition was placed on the burn area. Within 60 seconds the pain was approximately 60-70% under control. The pain was still lingering three minutes later.

20 A second thin layer of inventive composition was applied to the burn area, and within 60 seconds the remaining pain was gone. Fifteen to twenty minutes later the whiteness of the burned area on the fingers turned to a deep red. A few hours later, the redness was eliminated. After the second
25 application of the composition, no feeling of pain existed. There was no scarring and no blistering.

The next morning the patient immersed himself in a 105-106°F bath. The patient immersed his formerly burned hand in the bath with no effects. Usually when one is burned, if one
30 applies heat to the burned area, pain returns to that area. Here, the patient felt no such pain.

EXAMPLE 3

A patient had scalded herself with hot water from a bath. The patient dried herself off and immediately applied the inventive composition to the burn area. Within 30 minutes, 5 all of the pain and redness was gone, there was no scarring and no blistering.

EXAMPLE 4

A patient burned herself by placing her finger in boiling water. The finger was blistered and painful. The inventive 10 composition was applied to her finger. By the next day the person experienced no further pain, the blisters were gone and there was no scarring.

EXAMPLE 5

A patient had been overexposed to the sun. That evening 15 his skin was very red. The inventive composition was applied to the patient's face. Within a few hours the patient's face color had returned to normal, which contrasted with the red of the skin which had not had the inventive composition applied.

EXAMPLE 6

A patient had been burned when a lamp fell onto her arm. She immediately applied an over-the-counter burn medicine. This however did not stop the burning and a scab formed. Approximately one hour later the patient applied a small amount of the inventive composition on her blistered skin. 20 Almost instantly, the burning and throbbing stopped. In the morning the burn did not hurt and all of the surrounding redness was gone. For the next few mornings the patient reapplied the inventive composition. When the scab initially formed in the burned area before application of the inventive 25 composition fell off, there was no scar or no marks resulting 30

from the burn.

While the invention has been described in detail and with reference to specific preferred embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof.

5

What is claimed is:

1. A method for treating burns comprising topically administering to a burn area a composition comprising the combination of:

5 (a) tetracaine, in a concentration of from about 1% to 2% by weight; and

10 (b) sodium lauryl sulfate in a concentration of from about 0.5% to about 5.0% by weight and wherein said combination is administered in a pharmaceutically acceptable carrier for topical administration.

2. The method of claim 1 wherein said sodium lauryl sulfate has a concentration of about 1% by weight.

3. The method of claim 1 wherein said composition is applied to the burn area at least once twelve hours.

15 4. A method for treating burns comprising topically administering to a burn area a composition comprising the combination of:

20 (a) an anesthetic selected from the group consisting of esters, amides and ethers; and

 (b) a surfactant selected from the group consisting of anionic, nonionic and cationic surfactants.

25 5. The method of claim 4 wherein the anesthetic is approximately 0.05% to 25% by weight of said composition.

6. The method of claim 4 wherein the surfactant is approximately 0.05% to 50% by weight of said composition.

7. The method of claim 4 wherein the anesthetic is selected from the group consisting of procaine, chloroprocaine, tetracaine, propoxycaine, benzocaine, cocaine,

proparacaine, bupivacaine, etidocaine, lidocaine, mepivacaine, prilocaine, dyclonine and promazine.

8. The method of claim 4 wherein the surfactant is selected from the group consisting of monovalent salts, quaternary ammonium salts and polyethylene oxide adducts of fatty alcohols.

9. The method of claim 4 wherein the combination is administered in a pharmaceutically acceptable carrier.

INTERNATIONAL SEARCH REPORT

International application No. —
PCT/US97/13968

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 31/44
US CL : 514/299

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/299, 535; 424/70.19, 70.22, 70.27, 70.31

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG: Medline, BIOTECH, Conf. Papers, Euro, WPI
search terms: burn(s), treat?, therap?, pharmaceutical, tetracaine, sodium lauryl sulfate, surfactant(s), an(s)esthetic

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,002,974 A (GERIA) 26 March 1991; col. 2, paragraph 4; col. 3, paragraph 5; col. 4, lines 6-8; col. 5, lines 19-20; col. 6, lines 35-38; and col. 7, paragraph 6.	1-9
X	US 5,380,754 A (Miller et al.) 10 January 1995; abstract, col. 1, lines 20-23; col. 2 lines 14-68, col. 3, lines 1-4 and 44-45; and col. 20, lines 19-21.	1-9

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reasons (as specified)	"Y"	document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
C document referring to an oral disclosure, use, exhibition or other means	"Z"	document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
P document published prior to the international filing date but later than the priority date claimed	"A"	document number of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
06 OCTOBER 1997	17 NOV 1997

Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer Brenda Brumback Telephone No. (703) 308-0196
---	---

PROTECTOR DERMATOLOGICO GEL PARA QUEMADURAS

Número de patente: CO4700280 (A1)
Fecha de publicación: 1998-12-29
Inventor(es): GOMEZ TORRES HAROLD ARMANDO [CO]
Solicitante(s): DISNALET LTDA [CO]
Clasificación:
- internacional: A61K9/06; A61K38/43; A61K9/06; A61K38/43; (IPC1-7): A61K9/06; A61K38/43
- europea:
Número de solicitud: CO96007011 19960215
Número(s) de prioridad: CO96007011 19960215

Resumen de CO 4700280 (A1)

Se trata de un producto tópico en presentación GEL a base de carbopol, papaina y parabenos. Su objetivo es el tratamiento sintomático e inmediato de la quemadura y avulsiones superficiales cutáneas. El GEL forma una capa transparente sobre la lesión haciendo un efecto coloidal de apósito para aislarla del medio externo, cubre las terminales nerviosas y por lo tanto hay alivio del dolor. Sus componentes desinflaman, debitan y permiten rápida regeneración celular. También se previenen riesgos de sobreinfección. COMPOSICIÓN: GEL DE CARBOPOL: carbopol 2-2.5%, trietanolamina 2-2.5%, agua destilada hasta completar 100%. GEL DE CARBOXIMETIL CELULOSA: Methocel 3-3.5%, propil parabeno 0.2-0.5%, metil parabeno 0.2-0.5%, agua destilada hasta completar 100% Papaina 0.5-1.0%. PROCEDIMIENTO: Se colocan en un recipiente de acero inoxidable el gel de carbopol y el gel de carboximétíl celulosa, se mezclan y se les añade la papaina.

Data supplied from the esp@cenet database — LP - esp@cenet